US 12,435,135 B2
Human CD47-targeting single-domain antibody and use thereof
Xiangyu He, Shanghai (CN); Weihong Nian, Shanghai (CN); Chuanying Xu, Shanghai (CN); Xintong Zheng, Shanghai (CN); Xinmin Zhang, Shanghai (CN); Jing Xiao, Shanghai (CN); Feng He, Shanghai (CN); and Qing Zhou, Shanghai (CN)
Assigned to Shanghai Escugen Biotechnology Co., Ltd., Shanghai (CN)
Appl. No. 17/799,543
Filed by Shanghai Escugen Biotechnology Co., Ltd., Shanghai (CN)
PCT Filed Feb. 10, 2021, PCT No. PCT/CN2021/076479
§ 371(c)(1), (2) Date Aug. 12, 2022,
PCT Pub. No. WO2021/160153, PCT Pub. Date Aug. 19, 2021.
Claims priority of application No. 202010088990.4 (CN), filed on Feb. 12, 2020.
Prior Publication US 2023/0086530 A1, Mar. 23, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 1/00 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/3955 (2013.01); A61K 47/6849 (2017.08); A61P 1/00 (2018.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/35 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)] 23 Claims
 
1. An anti-CD47 heavy chain single-domain antibody (VHH), comprising CDRs of the following:
(1) CDR1, CDR2 and CDR3 as shown by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 respectively; or
(2) CDR1, CDR2 and CDR3 as shown by SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8 respectively.